Apogee Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $214.7M | $167.9M | $68.4M | $27.8M |
| SG&A Expense | $70.9M | $49.0M | $24.6M | $2.9M |
| Operating Income | $-285.6M | $-216.9M | $-93.0M | $-30.7M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | $-255.6M | $-182.1M | $-84.0M | — |
| Income Tax Expense | $278.0K | $18.0K | $0 | — |
| Net Income | $-255.8M | $-182.1M | $-84.0M | $-39.8M |
| Net Margin | — | — | — | — |
| EPS (Basic) | $-4.22 | $-3.30 | $-1.68 | $-0.81 |
| EPS (Diluted) | $-4.22 | $-3.30 | $-1.68 | $-0.81 |
| Shares Outstanding (Basic) | 60.7M | 55.2M | 50.0M | 49.2M |
| Shares Outstanding (Diluted) | 60.7M | 55.2M | 50.0M | 49.2M |
| Dividends Per Share | — | — | — | — |